Pfizer already got a major boost for its maternal RSV vaccine this week, when trials for GlaxoSmithKline’s rival shot were halted. And now the FDA has granted Pfizer a breakthrough therapy tag, which could allow the New York pharma to put the pedal to the metal and leave its U.K. peer in the dust.
The tag has been granted to Pfizer’s PF-06482077, or RSVpreF, to prevent lower respiratory tract illness in infants from birth to up to six months via immunization of pregnant women.
